Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Top Cited Papers
- 31 August 2004
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 40 (12), 1825-1836
- https://doi.org/10.1016/j.ejca.2004.04.030
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003
- Medical management of melanomaSurgical Clinics of North America, 2003
- Effects of interferon-α, verapamil and dacarbazine in the treatment of advanced malignant melanomaMelanoma Research, 2003
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patientsMelanoma Research, 2001
- Phase II Trial of Subcutaneous Interleukin-2, Subcutaneous Interferon-α, Intravenous Combination Chemotherapy, and Oral Tamoxifen in the Treatment of Metastatic Melanoma: Final Results of Cancer Biotherapy Research Group 94-11Cancer Biotherapy & Radiopharmaceuticals, 2000
- Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α2a and tamoxifen in metastatic melanomaMelanoma Research, 1999
- Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trialEuropean Journal of Cancer, 1998
- Interferon-α and chemohormonal therapy for patients with advanced melanomaCancer, 1998
- Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosoureaCancer, 1972